Sangamo Therapeutics

Showing 3 posts of 3 posts found.

Pfizer and Sangamo’s haemophilia gene therapy shows increased factor VIII levels

December 9, 2019
Manufacturing and Production, Sales and Marketing American Society of Hematology, Pfizer, Sangamo Therapeutics, hematology

Pfizer and Sangamo Therapeutics have revealed that their investigational gene therapy, SB-525, sustained increased factor VIII (FVIII) levels in patients …


Gilead seals $3bn deal, hoping for off-the-shelf CAR-T

February 23, 2018
Medical Communications, Sales and Marketing CAR-T, Gilead, Kite, Sangamo Therapeutics, biotech, drugs, pharma, pharmaceutical

The expense and laborious process involved in bringing CAR-T therapies to patients was used a key reason for the high …

Sangamo secures FDA’s Fast Track Designation for haemophilia candidate

May 17, 2017
Research and Development, Sales and Marketing FDA, Pfizer, Sangamo Therapeutics

Sangamo Therapeutics has announced that the FDA has granted its cDNA gene therapy candidate for haemophilia A Fast Track Designation. …

Latest content